A novel circular RNA hsa_circRNA_103809/miR-377-3p/GOT1 pathway regulates cisplatin-resistance in non-small cell lung cancer (NSCLC)

BACKGROUND: Cisplatin is the first-line chemotherapeutic drug for non-small cell lung cancer (NSCLC), and emerging evidences suggests that targeting circular RNAs (circRNAs) is an effective strategy to increase cisplatin-sensitivity in NSCLC, but the detailed mechanisms are still not fully delineate...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Xiang, Han, Jing, Lan, Huiyin, Lin, Qingren, Wang, Yuezhen, Sun, Xiaojiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7716498/
https://www.ncbi.nlm.nih.gov/pubmed/33276753
http://dx.doi.org/10.1186/s12885-020-07680-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7716498/
https://www.ncbi.nlm.nih.gov/pubmed/33276753
http://dx.doi.org/10.1186/s12885-020-07680-w

Ejemplares similares